MedTrace Logo

Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis

NCT02485613 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2015-06-30

No results posted yet for this study

Summary

Although the use of bortezomib has reported efficacy in amyloid light chain (AL) amyloidosis, the role of bortezomib with dexamethasone (BD) in the first-line treatment of patients with AL amyloidosis should be determined. In this study, the investigators evaluated the efficacy and safety of BD as the first-line treatment of patients with AL amyloidosis.

Conditions

  • Amyloidosis

Interventions

DRUG

bortezominb and dexamethasone

The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.

Sponsors & Collaborators

  • Zhi-Hong Liu, M.D.

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-12-31
Completion
2015-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02485613 on ClinicalTrials.gov